Literature DB >> 17289812

Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.

Angélique Biancotto1, Jean-Charles Grivel, Sarah J Iglehart, Christophe Vanpouille, Andrea Lisco, Scott F Sieg, Robert Debernardo, Kristen Garate, Benigno Rodriguez, Leonid B Margolis, Michael M Lederman.   

Abstract

There is growing recognition that HIV-1 infection leads to an activation of the immune system that includes perturbations of cytokine expression, redistribution of lymphocyte subpopulations, cell dysfunction, and cell death. Here, we explored the relationships between HIV-1 infection and immune activation in chronically HIV-1-infected human lymph nodes. In addition to CD4 T-cell depletion, we found increased effector T-cell frequencies associated with profound up-regulation of an activation marker CD38 in naive, central memory, and effector CD4(+) and CD8(+) T cells. Likewise, Fas death receptor (CD95) was more frequently detectable on T cells from HIV-1 nodes. Dendritic cell (DC) depletion was dramatic, with plasmacytoid DCs (PDCs) 40-fold and myeloid DCs (MDCs) 20-fold less frequent in HIV(+) nodes than in control nodes. Cytokine dysregulation was evident, with IL-2 and IL-15 as much as 2 or 3 logs greater in infected nodes than in control nodes. Thus, activated effector cells are inappropriately attracted and/or retained in lymphoid tissue in chronic HIV-1 infection. High-level cytokine expression in turn activates and retains more cells at these sites, leading to lymphadenopathy and massive bystander activation that characterizes HIV-1 infection. Strategies targeting these activation pathways may lead to new therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289812      PMCID: PMC1885500          DOI: 10.1182/blood-2006-11-055764

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes.

Authors:  S Deaglio; R Mallone; G Baj; A Arnulfo; N Surico; U Dianzani; K Mehta; F Malavasi
Journal:  Chem Immunol       Date:  2000

2.  Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.

Authors:  R A Lempicki; J A Kovacs; M W Baseler; J W Adelsberger; R L Dewar; V Natarajan; M C Bosche; J A Metcalf; R A Stevens; L A Lambert; W G Alvord; M A Polis; R T Davey; D S Dimitrov; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy.

Authors:  Barbara Schmidt; Sue H Fujimura; Jeffrey N Martin; Jay A Levy
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  Pathogenesis of HIV infection: what the virus spares is as important as what it destroys.

Authors:  Zvi Grossman; Martin Meier-Schellersheim; William E Paul; Louis J Picker
Journal:  Nat Med       Date:  2006-03       Impact factor: 53.440

5.  Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection.

Authors:  Timothy W Schacker; Jason M Brenchley; Gregory J Beilman; Cavan Reilly; Stefan E Pambuccian; Jodie Taylor; David Skarda; Matthew Larson; Daniel C Douek; Ashley T Haase
Journal:  Clin Vaccine Immunol       Date:  2006-05

Review 6.  Mechanisms of HIV-associated lymphocyte apoptosis.

Authors:  A D Badley; A A Pilon; A Landay; D H Lynch
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

7.  Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.

Authors:  Benigno Rodríguez; Ajay K Sethi; Vinay K Cheruvu; Wilma Mackay; Ronald J Bosch; Mari Kitahata; Stephen L Boswell; W Christopher Mathews; David R Bangsberg; Jeffrey Martin; Christopher C Whalen; Scott Sieg; Suhrida Yadavalli; Steven G Deeks; Michael M Lederman
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

8.  Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence.

Authors:  U Mahlknecht; C Deng; M C Lu; T C Greenough; J L Sullivan; W A O'Brien; G Herbein
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

9.  Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.

Authors:  J A Kovacs; R A Lempicki; I A Sidorov; J W Adelsberger; B Herpin; J A Metcalf; I Sereti; M A Polis; R T Davey; J Tavel; J Falloon; R Stevens; L Lambert; R Dewar; D J Schwartzentruber; M R Anver; M W Baseler; H Masur; D S Dimitrov; H C Lane
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

Review 10.  HIV disease: fallout from a mucosal catastrophe?

Authors:  Jason M Brenchley; David A Price; Daniel C Douek
Journal:  Nat Immunol       Date:  2006-03       Impact factor: 25.606

View more
  106 in total

Review 1.  Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.

Authors:  Michael L Freeman; Michael M Lederman; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  Accumulation of functionally immature myeloid dendritic cells in lymph nodes of rhesus macaques with acute pathogenic simian immunodeficiency virus infection.

Authors:  Viskam Wijewardana; Anthea L Bouwer; Kevin N Brown; Xiangdong Liu; Simon M Barratt-Boyes
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

3.  HIV-1-infected peripheral blood mononuclear cells enhance neutrophil survival and HLA-DR expression via increased production of GM-CSF: implications for HIV-1 infection.

Authors:  Jun Fu; Beverly E Sha; Larry L Thomas
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

4.  HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype.

Authors:  Simona Fiorentini; Elena Riboldi; Fabio Facchetti; Manuela Avolio; Marco Fabbri; Giorgio Tosti; Pablo D Becker; Carlos A Guzman; Silvano Sozzani; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-29       Impact factor: 11.205

Review 5.  Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history.

Authors:  Patricia Fitzgerald-Bocarsly; Jihong Dai; Sukhwinder Singh
Journal:  Cytokine Growth Factor Rev       Date:  2008-01-11       Impact factor: 7.638

Review 6.  Immune activation and the role of TLRs and TLR agonists in the pathogenesis of HIV-1 infection in the humanized mouse model.

Authors:  J Judy Chang; Marcus Altfeld
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

7.  Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.

Authors:  Carey L Shive; Joseph C Mudd; Nicholas T Funderburg; Scott F Sieg; Benjamin Kyi; Doug A Bazdar; Davide Mangioni; Andrea Gori; Jeffrey M Jacobson; Ari D Brooks; Jeffrey Hardacre; John Ammori; Jacob D Estes; Timothy W Schacker; Benigno Rodriguez; Michael M Lederman
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

8.  Interleukin-7 receptor signaling is deficient in CD4+ T cells from HIV-infected persons and is inversely associated with aging.

Authors:  Douglas A Bazdar; Magdalena Kalinowska; Scott F Sieg
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

9.  Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors.

Authors:  Wendy Fitzgerald; Nardhy Gomez-Lopez; Offer Erez; Roberto Romero; Leonid Margolis
Journal:  Am J Reprod Immunol       Date:  2018-05-04       Impact factor: 3.886

10.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.